IRADIMED's CEO Is Selling Steadily — The Plan, Not the Stock, Is Driving It

IRADIMED CEO Roger E. Susi sold 7,500 shares indirectly through a trust for approximately $691,000 as part of a systematic Rule 10b5-1 plan. The sale represents routine liquidation rather than a negative signal, with the stock up 60.89% over the past year. The key investment variable is the adoption of the company's new infusion pump, with meaningful data expected by mid-2027.